|
Glaxosmithkline Pharmaceuticals (India Infoline) Conviction Sell Ideas |
|
Topline growth to remain subdued; With 26% of products under price control margin expansion difficult to come by; Valuations expensive at P/E of 26x FY13E | Date | Rating | Target Price | Recommendation Price | Broker house | | 11 Jul 2011 | sell | 2016 | 2318 | India Infoline Report | |
|
Glaxosmithkline Pharmaceuticals (Citi) Growth to Pick Up, Valuations Rich |
|
Raise TP to 2,170;Growth Trajectory to Pick up;Changing Business Mix;Margin Expansion Limited | Date | Rating | Target Price | Recommendation Price | Broker house | | 24 Jun 2011 | sell | 2170 (from 2100) | 2329 | Citi Report | |
|
glaxosmithkline pharmaceutical (citi) Inline 1Q; DPCO Provision Hits Reported PAT |
Inline, steady; Steady revenue growth; EBITDA margin lower, PAT beats expectations; Provisions for DPCO-related demand pulls down reported PAT
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 8 May 2011 |
sell |
2100 |
2287 |
citi Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
glaxosmithkline pharma (Emkay) Steady business momentum; Maintain Hold |
Revenue growth led by traction across business units; EBITDA margins contraction led by higher raw material and other expenses; One-time provisioning dented bottom-line
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 6 May 2011 |
hold |
2161 |
2288 |
Emkay Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
glaxosmithkline pharma (Angel) Operating performance below estimates: |
|
glaxosmithkline pharmaceutical (Citi) Incorporating CY10 Annual Report Details |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 29 Mar 2011 |
sell |
2100 (from 2030) |
2085 |
Citi Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
glaxosmithkline pharma (MorganStanley) Stock Price Leveraged to Sales Growth - Retain EW |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 22 Feb 2011 |
equalweight |
2121 (from 1670) |
2223 |
MorganStanley Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
glaxosmithkline pharm (emkay) In-line results; Introduce CY12E and raise target price |
|
glaxosmithkline pharma (CreditSuisse) Focus on branded generics is positive but margin guidance remains subdued |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 21 Feb 2011 |
underperform |
1985 (from 1940) |
2223 |
CreditSuisse Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
glaxosmithkline pharmaceutical (Citi) Confident on Growth; Valuations Rich |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 20 Feb 2011 |
sell |
2030 |
2223 |
Citi Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
